Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 20, 2019 - Issue 5
Submit an article Journal homepage
4,118
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Important decisions in choosing the pharmacotherapy for narcoleptics

Stefano de BiaseNeurology Unit, Department of Neurosciences, University Hospital of Udine, Udine, ItalyView further author information
,
Gian Luigi GigliNeurology Unit, Department of Neurosciences, University Hospital of Udine, Udine, Italy;DMIF, University of Udine, Udine, ItalyCorrespondence[email protected]
View further author information
&
Mariarosaria ValenteNeurology Unit, Department of Neurosciences, University Hospital of Udine, Udine, Italy;Department of Medicine, University of Udine Medical School, Udine, ItalyView further author information
Pages 483-486 | Received 17 Oct 2018, Accepted 16 Dec 2018, Published online: 28 Dec 2018

References

  • Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16:9–18.
  • Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother. 2017;18:809–817.
  • Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654–2662.
  • American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. (ICSD-3). Rochester (MN): American Academy of Sleep Medicine; 2014.
  • Liblau RS, Vassalli A, Seifinejad A, et al. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14:318–328.
  • de Biase S, Nilo A, Gigli GL, et al. Investigational therapies for the treatment of narcolepsy. Expert Opin Investig Drugs. 2017;26:953–963.
  • Weinhold SL, Seeck-Hirschner M, Nowak A, et al. The effects of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014;262:8–13.
  • Black SW, Morairty SR, Chen TM, et al. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci. 2014;34:6485–6494.
  • Bogan R, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16:1102–1108.
  • Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39:1379–1387.
  • Schweitzer PK, Rosenberg R, Zammit GK, et al. 0641 A phase 3, randomized, placebo-controlled, double-blind, 12-week, multicenter study of the efficacy and safety of JZP-110 for the treatment of excessive sleepiness in patients with obstructive sleep apnea. Sleep. 2017;40(suppl. 1):A237.
  • Barateau L, Liblau R, Peyron C, et al. Narcolepsy type 1 as an autoimmune disorder: evidence, and implications for pharmacological treatment. CNS Drugs. 2017;31:821–834.
  • Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30:369–379.
  • Kotagal S. Treatment of narcolepsy and other organic hypersomnias in children. Paediatr Respir Rev. 2018;25:19–24.
  • Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29:939–946.
  • Cremaschi RC, Hirotsu C, Tufik S, et al. Chronic pain in narcolepsy type 1 and type 2 - an underestimated reality. J Sleep Res. 2018;e12715. [Epub ahead of print].
  • Vendrame M, Havaligi N, Matadeen-Ali C, et al. Narcolepsy in children: a single-center clinical experience. Pediatr Neurol. 2008;38:314–320.
  • Aran A, Einen M, Lin L, et al. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. Sleep. 2010;33:1457–1464.
  • Lecendreux M, Bruni O, Franco P, et al. Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res. 2012;21:481–483.
  • Plazzi G, Ruoff C, Lecendreux M, et al. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. Lancet Child Adolesc Health. 2018;2:483–494.
  • Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep. 2015;7:51–61.
  • Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12:1068–1075. EDS
  • Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:200–207.
  • Kumar S, Sagili H. Etiopathogenesis and neurobiology of narcolepsy: a review. J Clin Diagn Res. 2014;8:190–195.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.